Abstract:The neurotoxicity associated to the anticancer treatments has received a growing body of interest in the recent years. The development of innovating therapies over the last 20years has led to the emergence of new toxicities. Their diagnosis and management can be challenging in the clinical practice and further research is warranted to improve the understanding of their pathogenic mechanisms. Conventional treatments as radiation therapy and chemotherapy are associated to well-known and under exploration emerging central nervous system (CNS) and peripheral nervous system (PNS) toxicities. The identification of the risk factors and a better understanding of their pathogeny through a "bench to bedside and back again" approach, are the first steps towards the development of toxicity mitigation strategies. New imaging techniques and biological explorations are invaluable for their diagnosis. Immunotherapies have changed the cancer treatment paradigm from tumor cell centered to immune modulation towards an efficient anticancer immune response. The use of the immune checkpoints inhibitors (ICI) and CAR-T cells (chimeric antigen receptor) lead to an increase in the incidence of immune-mediated toxicities and new challenges in the neurological patient's management. The neurological ICI related adverse events (n-irAE) are rare but potentially severe and may present with both CNS and PNS involvement. The most frequent and well characterized, from a clinical and biological standpoint, are the PNS phenotypes: myositis and polyradiculoneuropathy, but the knowledge on CNS phenotypes and their treatments is expanding. The n-irAE management requires a good balance between dampening the autoimmune toxicity without impairing the anticancer immunity. The adoptive cell therapies as CAR-T cells, a promising anticancer strategy, trigger cellular activation and massive production of proinflammatory cytokines inducing frequent and sometime severe toxicity known as cytokine release syndrome and immune effector cell-associated neurologic syndrome. Their management requires a close partnership between oncologist-hematologists, neurologists, and intensivists. The oncological patient's management requires a multidisciplinary clinical team (oncologist, neurologist and paramedical) as well as a research team leading towards a better understanding and a better management of the neurological toxicities.

Theranostics advances in the treatment and diagnosis of neurological and neurosurgical diseases

Theranostics and artificial intelligence: new frontiers in personalized medicine

Recent Advances in Nanotherapeutics for Neurological Disorders

Theranostic Diagnostics

Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies

Advances in Neuro-Oncological Imaging: An Update on Diagnostic Approach to Brain Tumors

Translating the theranostic concept to neuro-oncology: disrupting barriers

Theranostics in the Arab World; Achievements & Challenges

Advanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's disease

Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents

Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging

Smart Nanoformulations for Brain Cancer Theranostics: Challenges and Promises

Nanoneuroscience: Cutting-edge Approach for Disease Management

Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects

Therapeutic Nanomaterials for Neurological Diseases and Cancer Therapy

Stem cell therapeutics and gene therapy for neurologic disorders

Theranostics Revolution in Prostate Cancer: Basics, Clinical Applications, Open Issues and Future Perspectives

The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy

Current Trends in Nanotheranostics: A Concise Review on Bioimaging and Smart Wearable Technology

Top advances of the year: Neuro-oncology

Radiotheranostics in oncology: Making precision medicine possible